DANIEL J. MAZANEC, M.D.
To the editor: Jacobs and colleagues (1) have addressed an important clinical problem in their study on management of the pregnant woman with Hodgkin's disease. Treatment directed at maintaining a high likelihood of cure while protecting the fetus is, as they indicate, the critical objective. However, their recommendation of therapeutic abortion for patients in the first trimester or first half of second trimester (20 weeks), except those with stage IA nonbulky neck or axillary disease, is not supported by their data or literature review. Moreover, this therapy obviously fails to achieve the second aspect of the treatment objective—protection of the
MAZANEC DJ. Pregnancy and Hodgkin's Disease. Ann Intern Med. ;96:531–532. doi: 10.7326/0003-4819-96-4-531
Download citation file:
Published: Ann Intern Med. 1982;96(4):531-532.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use